Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flonoltinib maleate - Chengdu Zenitar Biomedical Technology

Next Previous
Drug Profile

Flonoltinib maleate - Chengdu Zenitar Biomedical Technology

Alternative Names: Flonoltinib; Flonoltinib - Chengdu Zenitar Biomedical Technology; Flunotinib; Flunotinib - Chengdu Zenitar Biomedical Technology

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chengdu Zenitar Biomedical Technology
  • Class Antifibrotics; Antineoplastics; Antivirals
  • Mechanism of Action Cyclin-dependent kinase 6 inhibitors; Fms-like tyrosine kinase 3 inhibitors; Janus kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myelofibrosis; Polycythaemia vera
  • Preclinical Haemophagocytic lymphohistiocytosis
  • No development reported COVID 2019 infections

Most Recent Events

  • 19 Aug 2026 Chengdu Zenitar Biomedical Technology plans a phase I pharmacokinetics trial (In volunteers) in China (PO) (NCT07768111)
  • 10 Aug 2026 Chengdu Zenitar Biomedical Technology plans a phase II trial for Myelofibrosis in November 2026 (PO) (NCT07750574)
  • 31 Jul 2026 Chengdu Zenitar Biomedical Technology completes a phase I pharmacokinetics trial in Healthy volunteers in China (PO) (NCT07612306)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top